Research > Neurosciences

Neuroimmunology

• Overview
• Strategic lines
• Publications
• Members
• Projects

Regarding our lines of research:

• We carry out clinical research, since 2000 in the improvement of drugs for MS. Our team has participated in more than 70 national and international phase II, III and IV clinical trials, 8 of which are currently ongoing. This research is basically focused on finding drugs for ME that can reduce CNS inflammation in relapsing remitting forms and reduce neurodegeneration in progressive forms with a good safety profile.
• In terms of basic research:
  • We study the role of mitochondrial free radical production and molecular injury in biological samples from MS patients.
  • We are also studying the role that microglia may play in progressive forms of the disease and the prognostic role of cholesterol esters, a project for which the group has recently received an award (July 2022) from REEM (Spanish MS Network) and AEEM (Spanish Multiple Sclerosis Association).
  • We are also studying the early detection of cognitive impairment and the control of its progression throughout the disease.